Abstract 1204P
Background
Cholinesterase (CHE) as a routine serum biomarker in gastric cancer (GC). However, little research has been done on its clinical value in advanced GC. In addition, it is not clear whether it can be used as biomarker for the response and prognosis of advanced GC patients.
Methods
Between Jan. 2013 and Dec. 2016, a total of 150 patients with advanced GC treated with first-line chemotherapy were admitted to Changzhou Tumor Hospital Affiliated to Soochow University. We retrospectively identified serum CHE level before chemotherapy and abstracted clinicopathologic features and treatment outcomes. Univariate and multivariate survival analyses were performed to assess the relationship between serum CHE levels and progression-free survival (PFS) and overall survival (OS). Descriptive statistics were used to correlate level of CHE state and clinicopathological parameters.
Results
A total of 150 advanced GC patients were included and divided into positive and negative CHE values. CHE negative was associated with significant poorer progression-free survival (HR, 1.60; 95% CI, 1.141-2.243; P = 0.006), poorer overall survival (HR, 1.76; 95% CI, 1.228-2.515; P=0.002) and trend of poorer response (HR, 0.56; 95% CI, 0.272-1.129; P=0.104). The correlations were significant in multivariate analysis including PS score (P < 0.05). CHE positive was detectable in 93 of 150 (62%) postchemotherapy samples which was associated with a superior survival outcomes compared with patients in whom CHE became negative after chemotherapy.
Conclusions
Cholinesterase negative in the serum of advanced GC was significantly associated with poor PFS and OS. The results suggested that CHE analysis before chemotherapy was a promising prognostic marker for advanced GC. A post-chemotherapeutic CHE analysis may define a subset of patients who are still at high risk of becoming CHE negative even if they are CHE positive before chemotherapy. This high-risk group offers a unique opportunity to explore novel treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.